Beaver Run Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
- Meeting Program
- Meeting Summary
- Abstract Information
- Registration Information
- Scholarships / Awards
- Lodging / Hotels
- Travel / Transportation
- Conference Location
- Things to Do
- Services
- My Account
NOTES:
This meeting will be conducted in English.
All programs are subject to change. Check this site for updates.
Download Flyer
Twitter hashtag for this meeting: #KSantibodies
This meeting will be conducted in English.
All programs are subject to change. Check this site for updates.
Download Flyer
Twitter hashtag for this meeting: #KSantibodies
Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies (D2)
Scientific Organizers: Christian Klein, Mark S. Cragg and Germaine Fuh
April 7—11, 2019
Beaver Run Resort, Breckenridge, Colorado, USA
Sponsored by AbbVie Inc., Bioverativ Therapeutics, ImmunoGen, Inc., Incyte Corporation, Merck & Co., Inc., MorphoSys AG, Roche and Valerion Therapeutics
IT’S NOT TOO LATE TO SUBMIT YOUR ABSTRACT. Abstracts received can no longer be considered for oral short talks. Abstracts for poster display opportunities will be accepted until 6 weeks before meeting start date midnight MST.
BEWARE of booking lodging through companies unaffiliated with Keystone Symposia. Click here for more details.
Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.
DEADLINES:Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.
*All deadlines end at 11:59 PM US Mountain Standard Time
Scholarship Deadline: Dec 11, 2018 [details]
Discounted Abstract Deadline: Dec 11, 2018 [details]
Abstract Deadline: Jan 9, 2019 [details]
Discounted Registration Deadline: Feb 6, 2019 [details]
Click here to view Cancellation Policy
Discounted Abstract Deadline: December 11, 2018
*All deadlines end at 11:59 PM US Mountain Standard TimeAbstract Submission Fee: 100.00 USD*
Submission by this date receives 50.00 USD discount.
*50.00 USD will be applied to Registration Fee when you register
Abstract Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadlines. Submitting an abstract does not constitute or guarantee registration.
Submitting your abstract early allows us to:
- submit your abstract to organizers to be considered for a short talk
- accept your abstract online
- include your abstract on our website and in our secure mobile app
- reserve your space at the meeting for a poster presentation.**
(The Abstract Deadline: is January 9, 2019)
Global Health Travel Award Deadline:
*All deadlines end at 11:59 PM US Mountain Standard Time
Global Health Travel Award Details:
You MUST complete your Global Health Travel Award appplication by the Global Health Travel Award Deadline
and complete the other required steps (verify your contact information and submit a recommendation letter)
to be considered for a travel award.
Click here to learn more about Global Health Travel Awards.
Scholarship Deadline: December 11, 2018
*All deadlines end at 11:59 PM US Mountain Standard Time
Scholarship Details:
You MUST submit your abstract by the Scholarship Deadline and complete the other required steps (submit a scholarship application and submit a mentor letter) to be considered for a scholarship.
Abstract Deadline: January 9, 2019
*All deadlines end at 11:59 PM US Mountain Standard Time
Abstract Submission Fee: 100.00 USD*
*50.00 USD will be applied to Registration Fee when you register
Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadline. Submitting an abstract does not constitute or guarantee registration.
Submitting your abstract by the Abstract Deadline allows us to:
- submit your abstract to organizers to be considered for a short talk
- include your abstract on our website and in our secure mobile app
- reserve your space at the meeting for a poster presentation.**
Abstracts submitted after the Abstract Deadline will NOT be considered for a short talk.
(Discounted Abstract Deadline: is December 11, 2018)
Discounted Registration Deadline: February 6, 2019
*All deadlines end at 11:59 PM US Mountain Standard Time
Registration Fee: 845.00 USD* (includes 200.00 USD discount)
Student Registration Fee: 620.00 USD* (must complete student verification form)
*Includes 50.00 USD of your abstract submission fee
After the Discounted Registration Deadline:
Registration Fee: 1045.00 USD*
Student Registration Fee: 820.00 USD* (must complete student verification form)
*Includes 50.00 USD of your abstract submission fee
Registration spaces are limited and may fill prior to discounted registration deadline.
Please be advised that some meeting participants have received calls and emails from a number of different housing services,
including "Exhibitors Housing Services," “Expo Housing Services,” "Global Housing," etc. THESE COMPANIES ARE NOT AFFILIATED
WITH KEYSTONE SYMPOSIA and are not authorized by Keystone Symposia to contact you. These companies may tell you that the meeting
is filling, without any actual knowledge to that effect, and pressure you into giving them your credit card number to make a
lodging reservation with them.
We highly recommend that you not make a reservation with these companies or any other housing service! These companies' representations to participants have been misleading. Please report any calls or correspondence you might have received to Keystone Symposia and book only through lodging links in your Keystone Symposia account, an established travel agency or directly with the hotel(s) listed on our website.
We highly recommend that you not make a reservation with these companies or any other housing service! These companies' representations to participants have been misleading. Please report any calls or correspondence you might have received to Keystone Symposia and book only through lodging links in your Keystone Symposia account, an established travel agency or directly with the hotel(s) listed on our website.
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, April 7 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, April 11 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, April 12 in order to fully experience the meeting.
SUNDAY, APRIL 7
MONDAY, APRIL 8
TUESDAY, APRIL 9
WEDNESDAY, APRIL 10
THURSDAY, APRIL 11
FRIDAY, APRIL 12
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, April 7 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, April 11 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, April 12 in order to fully experience the meeting.
SUNDAY, APRIL 7
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:30
George D. Yancopoulos,
Regeneron Pharmaceuticals, Inc., USA
Target Identification and Developing Antibodies for Clinical Application
Target Identification and Developing Antibodies for Clinical Application
Jennifer R. Cochran,
Stanford University, USA
Emerging Strategies for Developing Next-Generation Protein Therapeutics
Emerging Strategies for Developing Next-Generation Protein Therapeutics
Coffee Break
09:50—12:00
Mechanisms of Action for Depleting Antibodies
Registered attendees can view abstracts starting on 03/07/2019
Registered attendees can view abstracts starting on 03/07/2019
Mark S. Cragg,
University of Southampton, UK
Targeting B Cells with Antibodies: From Oncology to Autoimmunity
Targeting B Cells with Antibodies: From Oncology to Autoimmunity
Falk Nimmerjahn,
Universitätsklinikum Erlangen, Germany
Optimal Formats for Target Cell Deletion
Optimal Formats for Target Cell Deletion
Annalee W. Nguyen,
University of Texas at Austin, USA
Short Talk: Antibodies Engineered for Enhanced Binding and Effector Activity in the Low pH of the Tumor Microenvironment
Short Talk: Antibodies Engineered for Enhanced Binding and Effector Activity in the Low pH of the Tumor Microenvironment
Polina Weitzenfeld,
Rockefeller University, USA
Short Talk:Antibody Targeting of Carbohydrate Associated Tumor Antigens Reveals Novel Effector Cell Pathways for Tumor Clearance
Short Talk:Antibody Targeting of Carbohydrate Associated Tumor Antigens Reveals Novel Effector Cell Pathways for Tumor Clearance
Michael Schmidt,
, USA
Short Talk: Novel Class of NK Engagers Targeting NKp30 Selected from Unbiased Screen of Common Light Chain Based Bispecific Antibodies
Short Talk: Novel Class of NK Engagers Targeting NKp30 Selected from Unbiased Screen of Common Light Chain Based Bispecific Antibodies
14:30—16:30
Workshop 1: Engineering (Bispecific) Antibodies
Starlynn Clarke,
TeneoBio Inc., USA
A Novel CD3xPSMA Bispecific Antibody for Efficient T-Cell Mediated Killing of Prostate Tumor Cells with Minimal Cytokine Release
A Novel CD3xPSMA Bispecific Antibody for Efficient T-Cell Mediated Killing of Prostate Tumor Cells with Minimal Cytokine Release
Lynn A. Kamen,
Genentech, Inc., USA
A Novel Cell-Based Assay for Predicting Bispecific Antibody Activity and its PK-PD Effects
A Novel Cell-Based Assay for Predicting Bispecific Antibody Activity and its PK-PD Effects
Jason Lajoie,
Compass Therapeutics, USA
A Versatile Platform for Efficient Affinity Optimization of Common Light Chain Bispecific Antibodies
A Versatile Platform for Efficient Affinity Optimization of Common Light Chain Bispecific Antibodies
Ahlam Qerqez,
University of Texas at Austin, USA
Human Cytomegalovirus-Specific T Cell Receptor Engineered for High Affinity and Soluble Expression using Mammalian Cell Display
Human Cytomegalovirus-Specific T Cell Receptor Engineered for High Affinity and Soluble Expression using Mammalian Cell Display
Diana Darowski,
Roche Gylcart AG, Switzerland
Antibodies as Drugs: P329G LALA Mutated Antibodies Enable Precise Redirection of Anti-P329G-Based Chimeric Antigen Receptor T Cells (P329G-CAR-T cells)
Antibodies as Drugs: P329G LALA Mutated Antibodies Enable Precise Redirection of Anti-P329G-Based Chimeric Antigen Receptor T Cells (P329G-CAR-T cells)
Koen Wagner†,
AIMM Therapeutics, Netherlands
AT1413 T-Cell Engager Activity is Determined by T-Cell Engager Format Valency
AT1413 T-Cell Engager Activity is Determined by T-Cell Engager Format Valency
Wei Yan,
Sound Biologics, USA
Development of MabPair Technology, A Novel Platform for Producing Bifunctional Antibody Products
Development of MabPair Technology, A Novel Platform for Producing Bifunctional Antibody Products
Brandy R. White,
California State University Fresno, USA
Humanization of a MUC16 Specific Monoclonal Antibody for the Treatment of Pancreatic Cancer
Humanization of a MUC16 Specific Monoclonal Antibody for the Treatment of Pancreatic Cancer
17:00—19:00
Janine Schuurman,
Genmab B.V., Netherlands
Engineering Non-Classical Antibody Formats Inspired by Nature
Engineering Non-Classical Antibody Formats Inspired by Nature
Feng Wang,
Institute of Biophysics, China
Engineering Antagonistic and Agonistic Antibodies
Engineering Antagonistic and Agonistic Antibodies
Germaine Fuh,
23andMe, USA
Engineering Antibody Specificity and Stability Using Deep Sequencing
Engineering Antibody Specificity and Stability Using Deep Sequencing
Aliza Borenstein-Katz,
Weizmann Institute, Israel
Short Talk: Optimization of Antibody Anti Pancreatic Cancer Marker
Short Talk: Optimization of Antibody Anti Pancreatic Cancer Marker
Chia Yin Lee,
Singapore Immunology Network, Singapore
Short Talk: Engineering the Fragment Crystallizable (Fc) Region of Antibody for Dendritic Cell-Based Vaccine
Short Talk: Engineering the Fragment Crystallizable (Fc) Region of Antibody for Dendritic Cell-Based Vaccine
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:45
Bispecific and Engineered Antibodies for Cancer Immunotherapy
Registered attendees can view abstracts starting on 03/07/2019
Registered attendees can view abstracts starting on 03/07/2019
Nai-Kong V. Cheung,
Memorial Sloan-Kettering Cancer Center, USA
Cancer Immunotherapy and Radioimmunotherapy with Bispecific Antibodies
Cancer Immunotherapy and Radioimmunotherapy with Bispecific Antibodies
Christian Klein,
Roche, Switzerland
Engineering Bispecific Antibodies for Combination Cancer Immunotherapy
Engineering Bispecific Antibodies for Combination Cancer Immunotherapy
Coffee Break
John R. Desjarlais,
Xencor, Inc., USA
Bispecific Antibodies for T Cell Recruitment and T Cell Activation
Bispecific Antibodies for T Cell Recruitment and T Cell Activation
Yvonne Y. Chen,
University of California, Los Angeles, USA
Engineering Next-Generation Chimeric Antigen Receptors
Engineering Next-Generation Chimeric Antigen Receptors
Udaya S Rangaswamy,
Teneobio, USA
Short Talk: A Novel T-Cell Bispecific Antibody Platform for Efficient T Cell Mediated Killing of Tumor Cells with Minimal Cytokine Release
Short Talk: A Novel T-Cell Bispecific Antibody Platform for Efficient T Cell Mediated Killing of Tumor Cells with Minimal Cytokine Release
Lina Bartels†,
AIMM Therapeutics & Amsterdam University Medical Center, Netherlands
Short Talk: A T-Cell Engager Based on A Unique AML Patient-Derived Anti-CD43 Antibody Has a Strong Anti-AML Activity in vivo Without Affecting Normal Hematopoietic Cells
Short Talk: A T-Cell Engager Based on A Unique AML Patient-Derived Anti-CD43 Antibody Has a Strong Anti-AML Activity in vivo Without Affecting Normal Hematopoietic Cells
Chad May,
Maverick Therapeutics, USA
Short Talk: COBRA: A Novel Conditionally Active Bispecific Antibody That Regresses Established Solid Tumors in Mice
Short Talk: COBRA: A Novel Conditionally Active Bispecific Antibody That Regresses Established Solid Tumors in Mice
17:00—19:00
David D. Ho,
Aaron Diamond AIDS Research Center, USA
Novel Antibodies for HIV Therapy and Prevention
Novel Antibodies for HIV Therapy and Prevention
JoAnn A. Suzich,
MedImmune, USA
Antibodies for Prevention and Treatment of Viral Infections
Antibodies for Prevention and Treatment of Viral Infections
Kartik Chandran,
Albert Einstein College of Medicine, USA
Catching Viruses in Endosome Using Bispecific Antibodies
Catching Viruses in Endosome Using Bispecific Antibodies
Sisi Shan,
Tsinghua University, China
Short Talk: Broad and Potent Bispecific Neutralizing Antibodies against Filovirus
Short Talk: Broad and Potent Bispecific Neutralizing Antibodies against Filovirus
Anna Zumsteg†,
Regeneron, USA
Short Talk: Staphylococcus Aureus Specific Monoclonal Antibodies that Escape Binding to Protein A Protect against Invasive Disease
Short Talk: Staphylococcus Aureus Specific Monoclonal Antibodies that Escape Binding to Protein A Protect against Invasive Disease
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:30
Ronit Mazor,
MedImmune, USA
Progress with Antibody Toxin Fusion Proteins and Overcoming Immunogenicity
Progress with Antibody Toxin Fusion Proteins and Overcoming Immunogenicity
Coffee Break
John M. Lambert,
, USA
The Promise of ADCs: A Simple Concept, Difficult to Execute! Where Are We Now?
The Promise of ADCs: A Simple Concept, Difficult to Execute! Where Are We Now?
W Michael Kavanaugh,
Cytomx Therapeutics, USA
Probody Therapeutics: Antibody Pro-drugs Designed for Safer and More Effective Cancer Therapies
Probody Therapeutics: Antibody Pro-drugs Designed for Safer and More Effective Cancer Therapies
Armine Matevossian,
Novartis Institutes for BioMedical Research, USA
Short Talk: Comprehensive Profiling of the Immune-Modulatory Properties of a Cytotoxic ADC Reveals Unique Contributions by the Antibody Component of the Drug
Short Talk: Comprehensive Profiling of the Immune-Modulatory Properties of a Cytotoxic ADC Reveals Unique Contributions by the Antibody Component of the Drug
Bradley Pearse,
Magenta Therapeutics, USA
Short Talk: Antibody Drug Conjugates as Targeted Conditioning Agents for Bone Marrow Transplant Patients
Short Talk: Antibody Drug Conjugates as Targeted Conditioning Agents for Bone Marrow Transplant Patients
Brian H. Santich,
Gerstner Sloan-Kettering Graduate School, USA
Short Talk: Self-Assembling and Disssembling (SADA) bispecific antibodies (BsAb) for 2-step Pretargeted RadioImmunotherapy (PRIT)
Short Talk: Self-Assembling and Disssembling (SADA) bispecific antibodies (BsAb) for 2-step Pretargeted RadioImmunotherapy (PRIT)
17:00—19:00
Joy Yu Zuchero,
Denali Therapeutics Inc, USA
CNS Delivery of Therapeutic Proteins using a Novel Fc Fragment Blood-Brain Barrier Transport Vehicle Approach
CNS Delivery of Therapeutic Proteins using a Novel Fc Fragment Blood-Brain Barrier Transport Vehicle Approach
Per-Ola Freskgård,
F. Hoffmann-La Roche, Switzerland
Crossing the Blood Brain Barrier with Antibodies to Access Brain Targets
Crossing the Blood Brain Barrier with Antibodies to Access Brain Targets
Allan Jensen,
Lundbeck, Denmark
Antibody based Therapies for Neurodegenerative Diseases
Antibody based Therapies for Neurodegenerative Diseases
Oosterlaken Mathieu,
Institut de Génomique Fonctionelle, France
Short Talk: Engineering Pharmacology Active Nanobodies to Target mGlu2 Receptor in the Brain
Short Talk: Engineering Pharmacology Active Nanobodies to Target mGlu2 Receptor in the Brain
Chiara Figazzolo,
University of Cambridge, UK
Short Talk: Rational Design and Systematic Optimization of Antibodies against the Aggregation of the Aβ42 Peptide
Short Talk: Rational Design and Systematic Optimization of Antibodies against the Aggregation of the Aβ42 Peptide
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:30
Bispecific Antibodies and Antibody Like Molecules
Registered attendees can view abstracts starting on 03/07/2019
Registered attendees can view abstracts starting on 03/07/2019
James A. Ernst,
Genentech, Inc., USA
A Bispecific Antibody Mimetic of FGF21 for the Treatment of Metabolic Disease and NASH
A Bispecific Antibody Mimetic of FGF21 for the Treatment of Metabolic Disease and NASH
Coffee Break
Andreas G. Plückthun,
University of Zürich, Switzerland
Engineering DARPins for Delivery into Cells
Engineering DARPins for Delivery into Cells
Krzysztof Masternak,
NovImmune SA, Switzerland
Bispecific CD47 Antibodies for Treatment of Cancer and Autoimmunity
Bispecific CD47 Antibodies for Treatment of Cancer and Autoimmunity
Peter J. Hudson†,
Avipep Pty Ltd, Australia
Short Talk: Engineered Antibody Fragments Precisely Loaded with Diagnostic and Therapeutic Payloads with First-in-Man Biodistribution in Cancer Metastases
Short Talk: Engineered Antibody Fragments Precisely Loaded with Diagnostic and Therapeutic Payloads with First-in-Man Biodistribution in Cancer Metastases
Leandrew A. Dailey†,
Albert Einstein College of Medicine, USA
Short Talk: Engineering Next Generation Bispecific Antibodies Against Filoviruses
Short Talk: Engineering Next Generation Bispecific Antibodies Against Filoviruses
14:30—16:30
Workshop 2: Antibodies for Immunological Applications
Nicole Piché-Nicholas,
Pfizer, USA
Changes in Complementarity-Determining Regions Significantly alter IgG Binding to the Neonatal Fc Receptor (FcRn) and Pharmacokinetics
Changes in Complementarity-Determining Regions Significantly alter IgG Binding to the Neonatal Fc Receptor (FcRn) and Pharmacokinetics
Trevor RF Smith,
Inovio Pharmaceuticals, USA
Active Immunoprophylaxis Employing DNA-Encoded Monoclonal Antibodies (dMAbs™)
Active Immunoprophylaxis Employing DNA-Encoded Monoclonal Antibodies (dMAbs™)
Olivia Vergnolle,
Albert Einstein College of Medicine, USA
Dengue Virus Glycoprotein E DIII Epitope Engineering for Broadly Neutralizing Antibodies Enhancement
Dengue Virus Glycoprotein E DIII Epitope Engineering for Broadly Neutralizing Antibodies Enhancement
Masahiro Yasunaga,
National Cancer Center, Japan
Development of Next-Generation Antibody Therapeutics against Cancer and Autoimmune Disease Utilizing DDS and Molecular Imaging
Development of Next-Generation Antibody Therapeutics against Cancer and Autoimmune Disease Utilizing DDS and Molecular Imaging
Henry Wilson,
The Scripps Research Institute, USA
A Sortase A Programmable Phage Display Format for Improved Panning of Fab Antibody Libraries
A Sortase A Programmable Phage Display Format for Improved Panning of Fab Antibody Libraries
Gregory Mann,
EPFL, Switzerland
Using Monobodies to Target Cytoplasmic Oncoproteins
Using Monobodies to Target Cytoplasmic Oncoproteins
17:00—18:45
Beyond Checkpoint Blockade: Novel Approaches for Immunotherapy
Registered attendees can view abstracts starting on 03/07/2019
Registered attendees can view abstracts starting on 03/07/2019
Mikael C. I. Karlsson,
Karolinska Institutet, Sweden
Anti-Marco Antibodies in Tumor Immunotherapy
Anti-Marco Antibodies in Tumor Immunotherapy
Sean Hua Lim,
University of Southampton, UK
Optimizing Anti-Tumour Immunity through Manipulation of the Innate-Adaptive Interface using CD27 Agonists
Optimizing Anti-Tumour Immunity through Manipulation of the Innate-Adaptive Interface using CD27 Agonists
Sapna Yadavilli,
GlaxoSmithKline, USA
GSK 3359609 a Non-T Cell Depleting IgG4 Anti-ICOS Antibody
GSK 3359609 a Non-T Cell Depleting IgG4 Anti-ICOS Antibody
Wen Jie Chin,
Agency for Science, Technology and Research, Singapore
Short Talk: Engineering Antibodies to Engage TRIM21 Improves Antigen Cross-Presentation in Human Monocyte-Derived Dendritic Cells
Short Talk: Engineering Antibodies to Engage TRIM21 Improves Antigen Cross-Presentation in Human Monocyte-Derived Dendritic Cells
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Registered attendees can view abstracts starting on 03/07/2019
Registered attendees can view abstracts starting on 03/07/2019
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors for generously supporting this meeting:
|
|
|
|
|
|
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Development, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org, Phone:+1 970-262-2676 |
